We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ACTT-2

News List

Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine prnewswire
December 14, 2020
Eli Lilly and Company and Incyte announced that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) ...
Baricitinib, Remdesivir Trial Reduces Recovery Time in Hospitalized COVID-19 Patients americanpharmaceuticalreview
September 21, 2020
Eli Lilly and Company and Incyte announced initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Baricitinib in combination with remdesivir reduces recovery time in hospitalised COVID-19 patients: Study expresspharma
September 16, 2020
Data from the Adaptive COVID-19 Treatment Trial (ACTT-2) revealed an approximately one-day reduction in median recovery time for the overall patient population.